Related Experiment Videos
Enzyme replacement therapy in mucopolysaccharidosis type I
1Children's Hospital, University of Mainz, Mainz, Germany. miebach@kinder.klinik.uni-mainz.de
Acta Paediatrica (Oslo, Norway : 1992). Supplement
|May 18, 2005
Summary
Enzyme replacement therapy (ERT) using laronidase is a safe and effective treatment for Mucopolysaccharidosis (MPS) type I, improving lung function and reducing liver size in patients with milder phenotypes.
Area of Science:
- Biochemistry
- Genetics
- Pharmacology
Background:
- Mucopolysaccharidosis (MPS) type I is a rare genetic disorder.
- It results from a deficiency in the alpha-L-iduronidase (IDUA) enzyme.
- MPS I presents with a broad range of clinical symptoms.
Purpose of the Study:
- To evaluate the safety and efficacy of enzyme replacement therapy (ERT) for MPS I.
- To assess the impact of laronidase on key clinical and biochemical markers.
Main Methods:
- Treatment of MPS I patients with recombinant human IDUA (laronidase) for 26 weeks.
- Assessment of pulmonary function (forced vital capacity) and exercise capacity (6-minute walk test).
- Monitoring of liver volume and urinary glycosaminoglycan excretion.
Main Results:
- Significant improvements observed in forced vital capacity and 6-minute walk test distance.
- Reduction in liver volume and urinary glycosaminoglycan levels.
- Laronidase was generally well-tolerated, with no severe adverse events; IgG antibodies declined over time.
Conclusions:
- ERT with laronidase shows promise as a therapeutic option for MPS I, particularly milder phenotypes.
- Laronidase may improve systemic health, potentially aiding other treatments like bone marrow transplantation.
- Central nervous system effects are not expected due to the blood-brain barrier.